The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

How A New Cure for Lupus Could Put Big Money in Your Pocket

By Malcolm Stacey | Tuesday 14 November 2017

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Hello Share Sloggers. Fancy investing in another AIM-listed company that is pioneering new medical treatments? Yes, I thought you might be a bit wary. But some of these ventures will come up roses, eventually.

The cash burn is usually scary, but finding new drugs is one of the most expensive undertakings you could find. Though it’s not long since I suggested ImmuPharma (IMM), it may be worth re-iterating my stance. The share has risen by about 10% since we last looked at it. Not massive, but it was only a month ago.

Its boffins are looking for treatments for autoimmune disease. The company has five potential drugs in stages of development. Its flagship drug is Lupuzor, a treatment for the serious immunity disease of lupus.

A month or so ago, it reported an interim loss of £3 million, and losses are normal in the medical pioneering game. But the damage was less than last time and the share price was invigorated. ImmuPharma had a fund-raising exercise in the Spring and now has assets of £6.4 million. But there’s no doubting the risks associated with this kind of company. They are probably even more speculative than gold prospectors.

Lupuzor is well into its trial period, with over a quarter of patients having completed the first year. And the company is beginning to think it will have the drug ready in the first three months of next year. That signals the board’s confidence in getting green lights from health watchdogs.

If its trials succeed, the company might produce and market drugs itself. Or one of the pharma giants could buy the licence. One advantage is that if any of the drugs do hit the jackpot then you’ll be making yourself richer and some desperately-ill people a lot happier.

Now let’s fall back to the Punter’s Return.

Filed under:

Never miss a story.

This area of the site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.

More on IMM


Comments are turned off for this article.

Site by Everywhen